Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.
This observational study is following people with Procedural Pain, Pain Catastrophizing, or Procedural Anxiety to understand outcomes over time. Participants mainly provide questionnaire, assessment, or follow-up information rather than receiving a new study treatment.
This study is looking at whether a digital support tool can help people with Cataract Surgery. Participants take part in a digital support tool and complete follow-up assessments.
This study is looking at whether a digital support tool can help people with Generalized anxiety. Participants take part in a digital support tool and complete follow-up assessments.
This study is looking at whether Safety Behavior Fading for Pathological Worry can help people with Generalized anxiety, Worrying, or Anxiety. Participants take part in Safety Behavior Fading for Pathological Worry and complete follow-up assessments.
This study is comparing Gaze-Contingent Music Reward Therapy with Sham-GCMRT for people with anxiety. Participants receive Gaze-Contingent Music Reward Therapy or Sham-GCMRT and complete study visits and assessments.
This study is looking at whether a digital support tool can help people with Breast Biopsy, Anxiety, or Pain. Participants take part in a digital support tool and complete follow-up assessments.
This study is comparing Fasedienol Nasal Spray - Placebo Nasal Spray with placebo for people with Social anxiety. Participants receive Fasedienol Nasal Spray - Placebo Nasal Spray or placebo and complete study visits and assessments.
This study is looking at care and outcomes for people with Schizophrenia or Autism-Related Irritability. Taking part may give some people access to KarXT, but direct benefit is not guaranteed.
This study is comparing N-Acetylcysteine with placebo for people with Prodromal Schizophrenia. Participants receive N-Acetylcysteine or placebo and complete study visits and assessments.
This study is looking at care and outcomes for people with Psychosis, Schizophrenia, At-risk Mental State, or Language Disorders. Some participants may receive healthy controls instead of the study treatment, and direct benefit is not guaranteed.
This study is looking at care and outcomes for people with Schizophrenia. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.
This study is looking at whether Paliperidone Palmitate Injection (3M) can help people with Schizophrenia. Participants receive a study treatment and complete follow-up visits and assessments.
This study is looking at care and outcomes for people with Schizophrenia. Some participants may receive Controls instead of the study treatment, and direct benefit is not guaranteed.
This study is looking at care and outcomes for people with Schizophrenia or Sensory Processing Disorder. Taking part may give some people access to a digital support tool, but direct benefit is not guaranteed.
This study is looking at whether NMDAE can help people with Schizophrenia. Participants take part in NMDAE and complete follow-up assessments.
This study is looking at care and outcomes for people with Schizophrenia Spectrum Disorder. Some participants may receive PFC sham instead of the study treatment, and direct benefit is not guaranteed.
This study is comparing NMDAE with placebo for people with Prodromal Schizophrenia. Participants receive NMDAE or placebo and complete study visits and assessments.
This study is looking at how safe and effective KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD is for people with Alzheimer Disease. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.
This study is looking at care and outcomes for people with Schizophrenia. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.
This study is comparing NMDAE plus AIFA with placebo for people with Schizophrenia. Participants receive NMDAE plus AIFA or placebo and complete study visits and assessments.
This study is looking at whether a digital support tool can help people with Clinical High Risk, Early Psychosis, or First Episode Psychosis. Participants take part in the therapy or support program and complete follow-up questionnaires or assessments.
This study is looking at assess the efficacy, safety, and tolerability of GXV813 in the treatment of an acute episode of schizophrenia. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.
This study is looking at care and outcomes for people with Psychosis of Childhood Borderline or psychosis. Taking part may give some people access to a digital support tool, but direct benefit is not guaranteed.
This study is looking at investigate neural markers in the cerebellar-cortical circuitry that predict treatment response to antipsychotics in first-episode psychosis for people with Psychosis or Acute. Participants are followed over time so researchers can learn from clinical and follow-up information.
This study is looking at whether MDMA 40mg can help people with Schizophrenia. Participants receive a study treatment and complete follow-up visits and assessments.